Please login to the form below

Not currently logged in

Deal Watch table for July 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during July 2013.

For an indepth analysis of these deals, read 'Pharma deals during July 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Elan / Perrigo Acquisition Tysabri royalty stream, R&D programmes/ EU HQ & operations 8,600
Trius Therapeutics / Cubist Pharmaceuticals Acquisition Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3) 818
*FibroGen / AstraZeneca Strategic collaboration FG-4592, oral treatment for anaemia in renal disease (p2/3) 815
Optimer Pharmaceuticals / Cubist Pharmaceuticals Acquisition Antibiotic pipeline based on Dificid (fidaxomicin) for C.difficile (approved) 801
Bever Pharmaceutical / Pharmstandard Acquisition Singapore-based pharma business 630
Immunocore / GSK Research collaboration and licence ImmTacs discovery platform against multiple targets 510
Quest Diagnostics / Royalty Pharma Purchase of royalty rights Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3) 485
Array BioPharma / Loxo Oncology Multi-year licence and collaboration Drug candidate (preclinical)+ discovery of small molecule drugs for oncology targets 434
Array BioPharma / Celgene Collaboration and option Programme targeting novel inflammation pathway (preclinical) 387
Ceptaris Therapeutics / Actelion Acquisition Valchlor for mycosis fungoides-type CTCL (NDA) 250
Syntaxin / Ipsen Acquisition of 90% stake Serenbotase (p2) and other recombinant botulinum toxins 210
Medicago / Mitsubishi Tanabe Pharma Acquisition of 60% stake Portfolio of flu and other vaccines based on VLPs (p2) 208
Talon Therapeutics / Spectrum Pharmaceuticals Acquisition Haemato-oncology portfolio, Marqibo for leukaemia (FDA approved) 206 + shares
Bionomics / Merck & Co Option and licence ionX drug discovery and MultiCore chemistry platform (discovery) 172
Nerviano Medical Sciences / Servier  Collaboration, licence, option Protein kinase TTK/MPS1 inhibitors (preclinical) 143
Lilly / Transition Therapeutics Licence, collaboration and option*‡ TT-601 for osteoarthritis pain (preclinical) 130*‡
**Vivus / Berlin-Chemie  (Menarini) Licence, commercialisation, supply Spedra (avanafil) for erectile dysfunction (approved) 121
‡Optinose / Avanir Pharmaceuticals Licence Breath Powered intranasal sumatriptan for migraine (p3) 110
Acetylon Pharmaceuticals / Celgene Collaboration and option to acquire HDAC inhibitors inc ACY-1215 for multiple myeloma (p1b) 100
‡‡Servier / Amgen   Cardiovascular collaboration, licence and option Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2)  50
Opalia Pharma / Recordati   Acquisition of 90% stake Branded generic drugs - dermatology, GI, respiratory  49
†Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum  Development, supply and commercialisation Xiapex (collagenase clostridium histolyticum) (approved)   40

All deals are worldwide unless otherwise noted – see below:
*  US, China and all major markets ex Japan, Europe, CIS, Middle East, South Africa 
**  Over 40 European countries, Australia, New Zealand 
‡  North America
‡‡  Amgen receives US  rights to Servier's ivabradine and an exclusive option to Servier's S-38844 in the US; Servier receives rights in Europe for omecamtiv mecarbil
†  EU

*‡  Payable to Transition Therapeutics if Lilly exercises its option to re-acquire at clinical proof of concept
ImmTacs = Immune mobilising mTCR against cancer
CLL = chronic lymphocytic leukaemia
CTCL = cutaneous T-cell lymphoma
VLP  = virus-like particle produced in plant expression systems 



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....